AbbVie Inc $47.86

up +1.03


15/4/2014 06:40 PM  |  NYSE : ABBV  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get ABBV Trend Analysis - it has underperformed the S&P 500 by 3%

Partner Headlines

  1. AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) ...

    Benzinga
  2. Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings

    Benzinga
  3. Benzinga's Top #PreMarket Losers

    Benzinga
  4. HCV Rivalry Heats Up As Merck Combo Shines In Trial

    IBD
  5. Merck Hepatitis C Combo Scores 98% Cure Rate

    IBD
  6. UPDATE: Morgan Stanley Reiterates, Removes PT on AbbVie on Potential of ...

    Benzinga
  7. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  8. Baxter Splitting In Effort To 'Unlock Trapped Value'

    IBD
  9. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  10. TripAdvisor: Yelp of Travel Looks Too Pricey

    YCharts
  11. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  12. House Probe Of Gilead's Sovaldi Price Hits Biotechs

    IBD
  13. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  14. Lountzis Asset Management Comments on Abbvie

    GuruFocus
  15. Gilead Pricing Probed By House; Biotech Stocks Drop

    IBD
  16. Gilead's HCV Challengers Near The Starting Gate

    IBD
  17. Gilead's HCV Challengers Near The Starting Gate

    IBD
  18. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  19. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  20. Pharma Patent Cliff: Why Worst Seems Over

    YCharts
  21. UPDATE: Bank of America Reiterates on AbbVie on Higher HCV Sales

    Benzinga
  22. Investors Brace for Bear Market

    FoxBusiness
  23. AbbVie’s Testosterone: Impact of Health Concerns

    YCharts
  24. #PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over ...

    Benzinga
  25. Earnings Scheduled For January 31, 2014

    Benzinga
  26. We Were Dividends, Before Dividends Were Cool

    GuruFocus
  27. Abbott Labs Q4 Sales Miss Estimates; Earnings In Line

    IBD
  28. AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage ...

    Benzinga
  29. Enanta Joins Big Leagues With Hepatitis C Drug

    IBD
  30. BofA Merrill Lynch Reiterates on AbbVie, Raises PO

    Benzinga
  31. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  32. Drugmaker Aptalis Files For IPO After Overhaul

    IBD
  33. Benzinga's Top Downgrades

    Benzinga
  34. S&P Stocks Hitting New Highs

    FoxBusiness
  35. Co-Pays: Skin In the Game If It Ain’t Your Skin?

    YCharts
  36. Gilead's Next Hepatitis C Drug A Hit In Trials

    IBD
  37. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  38. UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia ...

    Benzinga
  39. Drug trials cut new FDA path

    IBD
  40. Gilead knocked on drug price

    IBD
  41. Gilead HCV Drug May Face Price War; Rival AbbVie Up

    IBD
  42. Gilead Potential Blockbuster Hep C Drug Wins FDA Nod

    IBD
  43. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD
  44. Market Wrap For December 3: Markets Finish In The Red For Third Straight ...

    Benzinga
  45. After Top-Seller Remicade: Analysis of J&J’s Future

    YCharts
  46. Gilead Hepatitis C Drug Wins EU Panel Vote Early

    IBD
  47. J&J’s Top Drug vs. Generic: Investment Thesis

    YCharts
  48. #PreMarket Primer: Friday, November 22: Draghi Defends ECB Rate Cut

    Benzinga
  49. AbbVie hepatitis C drug shines

    IBD
  50. AbbVie Hepatitis C Treatment Shines In Latest Trials

    IBD
Trading Center